Cancer Cell:多梳蛋白4(Cbx4)与肝癌生存期密切相关

2014-03-21 佚名 健康报

上海交通大学医学院细胞分化和凋亡教育部重点实验室陈国强教授领衔的课题组科研人员历时6年,在多梳蛋白4(Cbx4)干预肝癌组织新生血管生成研究方面取得突破,相关研究论文日前发表在国际学术刊物《癌细胞》杂志上。专家认为,Cbx4与肝癌病人的生存期密切相关,有望成为临床上判断肝癌预后的指标;同时发现Cbx4通过泛素蛋白修饰调控肝癌的新生血管生成,为肝癌治疗提供新启示。 既往

上海交通大学医学院细胞分化和凋亡教育部重点实验室陈国强教授领衔的课题组科研人员历时6年,在多梳蛋白4(Cbx4)干预肝癌组织新生血管生成研究方面取得突破,相关研究论文日前发表在国际学术刊物《癌细胞》杂志上。专家认为,Cbx4与肝癌病人的生存期密切相关,有望成为临床上判断肝癌预后的指标;同时发现Cbx4通过泛素蛋白修饰调控肝癌的新生血管生成,为肝癌治疗提供新启示。

既往研究认为,高密度的新生血管生成在肝癌的发生、发展和转移过程中发挥了重要作用,但既往研究中缺少特异性抑制新生血管生成的靶点蛋白。

陈国强课题组科研人员通过检测727位肝癌病人癌组织样本中多梳蛋白4(Cbx4)的表达,发现高表达Cbx4的肝癌病人手术后5年生存期明显低于低表达Cbx4的肝癌病人,科研人员由此提出Cbx4是独立判断肝癌病人预后的重要指标。在此基础上,科研人员又进一步发现,Cbx4的表达水平与血管内皮生长因子(VEGF)的表达及新生血管密度呈高度正相关,即在多种皮下与原位肝癌实验小鼠模型中,Cbx4高表达促进VEGF的产生、新生血管生成和肿瘤的生长与转移;反之,抑制Cbx4表达则明显抑制甚至阻止肝癌细胞在小鼠体内的生长,从而揭示了Cbx4在肝癌发生、发展中的重要作用。

原始出处:

Li J, Xu Y, Long XD, Wang W, Jiao HK, Mei Z, Yin QQ, Ma LN, Zhou AW, Wang LS, Yao M, Xia Q, Chen GQ.Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.Cancer Cell. 2014 Jan 13;25(1):118-31.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780618, encodeId=66621e806183f, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 24 15:25:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959036, encodeId=216619590369c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 26 21:25:00 CST 2014, time=2014-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868793, encodeId=f2d91868e9328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 01:25:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981197, encodeId=de7e198119efb, content=<a href='/topic/show?id=a8374329eea' target=_blank style='color:#2F92EE;'>#多梳蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43297, encryptionId=a8374329eea, topicName=多梳蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Aug 01 10:25:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378043, encodeId=e39413e8043a8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Mar 23 07:25:00 CST 2014, time=2014-03-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780618, encodeId=66621e806183f, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 24 15:25:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959036, encodeId=216619590369c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 26 21:25:00 CST 2014, time=2014-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868793, encodeId=f2d91868e9328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 01:25:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981197, encodeId=de7e198119efb, content=<a href='/topic/show?id=a8374329eea' target=_blank style='color:#2F92EE;'>#多梳蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43297, encryptionId=a8374329eea, topicName=多梳蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Aug 01 10:25:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378043, encodeId=e39413e8043a8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Mar 23 07:25:00 CST 2014, time=2014-03-23, status=1, ipAttribution=)]
    2014-12-26 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780618, encodeId=66621e806183f, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 24 15:25:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959036, encodeId=216619590369c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 26 21:25:00 CST 2014, time=2014-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868793, encodeId=f2d91868e9328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 01:25:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981197, encodeId=de7e198119efb, content=<a href='/topic/show?id=a8374329eea' target=_blank style='color:#2F92EE;'>#多梳蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43297, encryptionId=a8374329eea, topicName=多梳蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Aug 01 10:25:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378043, encodeId=e39413e8043a8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Mar 23 07:25:00 CST 2014, time=2014-03-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780618, encodeId=66621e806183f, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 24 15:25:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959036, encodeId=216619590369c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 26 21:25:00 CST 2014, time=2014-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868793, encodeId=f2d91868e9328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 01:25:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981197, encodeId=de7e198119efb, content=<a href='/topic/show?id=a8374329eea' target=_blank style='color:#2F92EE;'>#多梳蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43297, encryptionId=a8374329eea, topicName=多梳蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Aug 01 10:25:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378043, encodeId=e39413e8043a8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Mar 23 07:25:00 CST 2014, time=2014-03-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780618, encodeId=66621e806183f, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 24 15:25:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959036, encodeId=216619590369c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 26 21:25:00 CST 2014, time=2014-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868793, encodeId=f2d91868e9328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 01:25:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981197, encodeId=de7e198119efb, content=<a href='/topic/show?id=a8374329eea' target=_blank style='color:#2F92EE;'>#多梳蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43297, encryptionId=a8374329eea, topicName=多梳蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Aug 01 10:25:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378043, encodeId=e39413e8043a8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Mar 23 07:25:00 CST 2014, time=2014-03-23, status=1, ipAttribution=)]

相关资讯

WJG:抗病毒治疗对肝脏肿瘤形成和肝癌再发的影响

治疗用抗病毒药物如作为核苷(酸)类似物(Nucs)或干扰素(IFN)-α可以迅速抑制HBV复制,从而减少纤维化的进展和HCC的发生。虽然局部或全身的化疗可以治疗肿瘤,但手术切除或肝移植仍是治疗HCC的最有效方法。术后HCC复发是常见的现象。预防乙肝相关性肝癌的发生和复发需要接受综合性治疗,这一观点已得到广泛的认识。 因此,来自南京医科大学附属第一医院的研究人员综述了HBV诱导肝癌的机制,讨论

微波固化可使肝癌切除手术更安全

近日,解放军第302医院成功完成了世界首例腹腔镜下微波消融技术辅助肝癌切除手术。据介绍,该技术有效解决了肝癌切除中的止血难题,并可减少肿瘤局部复发转移风险。 今年11月,患者陈女士在体检中发现肝脏左叶长了一个直径1.5厘米左右的巨大血管瘤,遂入解放军第302医院普通外科就诊。经过进一步检查,医生发现该血管瘤位置紧贴肝脏主干血管,如按常规腹腔镜下肿瘤切除方法进行手术,很

Cancer Cell:多梳蛋白4与肝癌生存期密切相关

上海交通大学医学院细胞分化和凋亡教育部重点实验室陈国强教授领衔的课题组科研人员历时6年,在多梳蛋白4(Cbx4)干预肝癌组织新生血管生成研究方面取得突破,相关研究论文日前发表在国际学术刊物《癌细胞》杂志上。专家认为,Cbx4与肝癌病人的生存期密切相关,有望成为临床上判断肝癌预后的指标;同时发现Cbx4通过泛素蛋白修饰调控肝癌的新生血管生成,为肝癌治疗提供新启示。【原文下载】 肝癌的发病率和致死率

Science:一种罕见肝癌与嵌合基因DNAJB1-PRKACA异常基因突变有关

日前,来自洛克菲勒大学与纪念斯隆-凯特琳癌症中心等机构的研究人员在《科学》杂志上报告称,他们可能更进一步地获得了对一种影响青少年及年轻成年人的罕见肝癌的分子发病机制的理解。纤维板层肝细胞癌(FL-HCC)是一种侵袭性的肝癌,针对这种癌症除了手术之外还没有有效的治疗方法。人们对其分子发病特征了解甚少,其部分原因是因为该肿瘤是如此罕见,而采集足够数目的肿瘤样本来做基因分析一直是富有挑战性的。 与正常

美国肝病研究学会肝癌诊治指南诊断要点

许多国家,肝癌(HCC)的发生率逐渐升高。肝癌患者的治疗需要多学科的参与,包括肝脏内科、外科、肝移植小组、肿瘤科、介入科及放疗科。HCC的发生通常有相关的肝病背景,因此在治疗前、治疗过程中及治疗后对肝功能损害的评估显得尤为重要。监测及评估HCC高危人群筛查发现肝脏小结节病变时的检查流程1、具有发生HCC高危风险的患者,应纳入监测程序(I级)。2、列入移植名单上等待肝移植的患者应进行HCC筛查,因为